*ST Tianmao Faces Delisting Risk Amid Trading Anomaly

*ST Tianmao (formerly Hubei Biocause Pharmaceutical) disclosed abnormal stock trading, with prices declining over 12% across three consecutive trading days (July 25, 28, and 29, 2025). This follows a delisting risk warning issued on July 8, 2025, after the company failed to release its 2024 annual report and Q1 2025 report by the May 6, 2025, deadline. The China Securities Regulatory Commission initiated an investigation on May 6, 2025. If the reports are not disclosed within two months of the delisting warning, the company faces termination of its stock listing.